ArticleDermatology and therapy2025

Efficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized Study.

Stefan J Jodl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.